Envita México

Prostate Cancer Treatment with AAIT™: A New Horizon in Immunotherapy

AAIT™ in Metastatic Castrate-Resistant Prostate Cancer 

Autologous Adoptive Immunotherapy (AAIT™) presents a promising avenue for cancer management, based on recent findings and advancements in the field of immunotherapy for prostate cancer. This personalized immunotherapy harnesses the patient’s own immune cells, targeting and eradicating cancer cells with precision.

AAIT™ has demonstrated significant potential in targeting prostate cancer stem-like cells, utilizing the interactivity between peptide-sensitized dendritic cells and cytokine-induced Natural Killer (NK) cells [1]. This class of medicine has shown efficacy in not just recognizing but also eliminating cancerous cells while sparing healthy tissues. This precision targeted approach minimizes side effects that are typically seen with conventional treatments.

Gradual Transition from Clinical Trials to Standard of Care

AAIT™ has been in clinical trials for years and is being increasingly adopted for standard care. Sipuleucel-t is an autologous cellular immunotherapy, which has been recently approved for the treatment of asymptomatic or minimally symptomatic metastatic, castrate-resistant prostate cancer [2]. While not approved for later stages of disease, Sipuleucel-t therapy exemplifies the practical application of the underlying procedure utilized in AAIT™. In both these treatment approaches the patient’s immune cells are collected to be exposed to a prostate cancer antigen, and the expanded cells are then reintroduced back into the patient. However, AAIT™ further personalizes this precision targeted immunotherapy to enhance outcomes.

This form of immunotherapy aims to elicit a targeted immune response against prostate cancer cells. AAIT™ has opened new avenues for prostate cancer treatment, expanding the role of the innate immune system in improving response rates and paving the way for combination therapies, alongside other immunomodulating agents, chemotherapy, or radiation. 

Enhancing Cancer Care with AAIT™: A Targeted Approach 

AAIT™ represents a shift in how doctors approach the treatment of prostate cancer, with a greater focus on personalized medicine as a means of obtaining better responses. This innovative treatment modality is based on the concept of highly personalized medicine and harnessing your own immune cells to target and dismantle cancer cells [3]. The customized nature of AAIT™ ensures that the treatment is uniquely tailored for your specific disease characteristics, which enhances efficacy and reduces the likelihood of side effects compared to a one-size-fits-all approach. 

The reason why a personalized approach is so beneficial for cancer care is the capacity to accommodate the genetic and molecular diversity inherent to each individual’s tumor [4]. Prostate cancer, like many other cancers, exhibits significant heterogeneity, meaning that a treatment which is effective for one patient may not be as effective for another [5]. AAIT™ navigates the complexity of this disease by analyzing the unique tumor markers present in each patient, enabling a precise targeting of cancer cells without harming healthy tissue [6]. This specificity maximizes the therapeutic effect of the treatment and also minimizes collateral damage, a defining trait of chemotherapy and radiation therapy [7]. In this way, the physicians at Envita Medical Centers, Mexico, seek to improve patient outcomes while maintaining quality of life. 

At Envita, we are seeking to develop a more dynamic treatment strategy by building the concept of personalized medicine into AAIT™ from the outset. By bolstering the patient’s own immune response to cancer and training those cells to recognize and attack cancer cells present in the body, AAIT™ offers a robust defense against the challenge of tumor resistance to therapy [8].

AAIT™ provides critical adaptability to the patient’s unique presentation of disease by adapting to the patient’s cancer cells, collected through biopsy and blood collection. This form of treatment can not only overcome resistance to conventional care, but also enhance the function of other simultaneous immunotherapies and conventional therapies like chemotherapy and radiation [9]. Focusing on the genetic and molecular profile of each individual’s unique strain of cancer exemplifies AAIT™ as a leader in the frontier of personalized medicine. With this revolutionary personalized precision immunotherapy, we at Envita hope to offer a new avenue of treatment for prostate cancer patients. 

Future Directions in Prostate Cancer Therapy: Where does AAIT™ Fit?

AAIT™ is an emerging approach to prostate cancer care that offers a transformative new hope for advanced and treatment-resistant stages of prostate cancer, as well as early-stage cancer. This innovative therapy harnesses the patient’s own immune system to create a tailored attack against your unique strain of cancer. At Envita, we’re working to revolutionize how prostate cancer is treated at every stage. The results of clinical trials indicate that the future of prostate cancer therapy lies in personalized medicine [10-12].

By addressing the tumor microenvironment and overcoming resistance mechanisms, AAIT™ aims to position itself for this future. One of the benefits of focusing on adoptive immunotherapy for prostate and other kinds of cancer is that the treatment is effective both at the early and advanced or resistant stages of the disease. Additionally, AAIT™ works well as an adjuvant treatment, synergizing with other forms of immunotherapy and even radiation and chemotherapy as well. These synergistic features, along with continuing clinical trials into autologous adoptive cell therapy, indicate that treatments like AAIT™ will have a large part to play in the future of prostate cancer treatment.


  1. Taborska, Pavla, et al. “Abstract B065: Use of Simultaneous Detection of Externalized CD107a and CD137 for Evaluation of Specificity and Effector Functions of Polyclonal T-Cells Produced for Adoptive Cellular Immunotherapy of Prostate Cancer.” Cancer Immunology Research, vol. 4, no. 11_Supplement, 2016, pp. B065–B065, https://doi.org/10.1158/2326-6066.IMM2016-B065.
  2. Di Lorenzo, Giuseppe, et al. “Sipuleucel‐T (Provenge®) for Castration‐resistant Prostate Cancer.” BJU International, vol. 110, no. 2b, 2012, pp. E99–104, https://doi.org/10.1111/j.1464-410X.2011.10790.x.
  3. Jewett, Anahid, and Yuman Fong, editors. NK Cells in Cancer Immunotherapy : Successes and Challenges. Academic Press, 2023.
  4. Omelchuk, E. P., et al. “Molecular Genetic Aspects of Prostate Cancer Radioresistance.” Bi͡u︡lletenʹ Sibirskoĭ Medit͡s︡iny, vol. 20, no. 3, 2021, pp. 182–92, https://doi.org/10.20538/1682-0363-2021-3-182-192.
  5. Wang, Zhu A., et al. “Lineage Analysis of Basal Epithelial Cells Reveals Their Unexpected Plasticity and Supports a Cell-of-Origin Model for Prostate Cancer Heterogeneity.” Nature Cell Biology, vol. 15, no. 3, 2013, pp. 274–83, https://doi.org/10.1038/ncb2697.
  6. Yordanova, Anna, et al. “The Value of Tumor Markers in Men with Metastatic Prostate Cancer Undergoing [177Lu]Lu‐PSMA Therapy.” The Prostate, vol. 80, no. 1, 2020, pp. 17–27, https://doi.org/10.1002/pros.23912.
  7. Nada, Mohanad H., et al. “PD-1 Checkpoint Blockade Enhances Adoptive Immunotherapy by Human Vγ2Vδ2 T Cells against Human Prostate Cancer.” Oncoimmunology, vol. 10, no. 1, 2021, pp. 1989789–1989789, https://doi.org/10.1080/2162402X.2021.1989789.
  8. Alberti, Contardo. “Prostate Cancer Immunotherapy, Particularly in Combination with Androgen Deprivation or Radiation Treatment. Customized Pharmacogenomic Approaches to Overcome Immunotherapy Cancer Resistance.” Il Giornale Di Chirurgia, vol. 37, no. 5, 2017, pp. 225–35, https://doi.org/10.11138/gchir/2016.37.5.225. 
  9. Bilusic, Marijo, et al. “Immunotherapy of Prostate Cancer: Facts and Hopes.” Clinical Cancer Research, vol. 23, no. 22, 2017, pp. 6764–70, https://doi.org/10.1158/1078-0432.CCR-17-0019.
  10. Rezaei, Nima. Vaccines for Cancer Immunotherapy : An Evidence-Based Review on Current Status and Future Perspectives. Academic Press, an imprint of Elsevier, 2019.
  11. Pinthus, Jehonathan H., et al. “Adoptive Immunotherapy of Prostate Cancer Bone Lesions Using Redirected Effector Lymphocytes.” The Journal of Clinical Investigation, vol. 114, no. 12, 2004, pp. 1774–81, https://doi.org/10.1172/JCI200422284.
  12. Haiyuan, Yu, et al. “CART Cell Therapy for Prostate Cancer: Status and Promise.” OncoTargets and Therapy, vol. 12, 2019, pp. 391–95, https://doi.org/10.2147/OTT.S185556.

Disclaimer: The information on this website is for educational purposes only and not intended as medical advice. Always consult with a qualified healthcare provider for medical advice and treatment options.

Choose Envita Medical Centers

Would you like to learn more about treatment options? Send us a message and we will be in touch shortly or call 1-866-830-4576.

Personal Information

Enter your date of birth.

Contact Preferences